Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgA

RWTH Aachen0 个研究点目标入组 148 人开始时间: 2007年11月27日最近更新: 2015年7月10日

试验速览

暂无简介。

•- Male or female patients from 18-70 years with histologically proven primary IgAN with typical mesangioproliferative features. Diagnosis has to be made by a nephropathologist. - Proteinuria above 0.75 g/day within 12 weeks prior to or at the first visit in the run-in phase (month -6) and presence of at least one further risk factor for the development of end stage renal disease a) arterial hypertension, defined as ambulatory blood pressure >140/90 mm Hg or the use of antihypertensive medication or b) impaired renal function, defined as creatinine clearance or estimated GFR <90 ml/min.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Known allergy or intolerance to study medication (except in case of ACE-inhibitor, in which case a change to an angiotensin receptor blocker is possible). - Women who are pregnant or breastfeeding. - Women without sufficient contraception. - Contraindication for immunosuppressive therapy - Any prior immunosuppressive therapy. - Variants of primary IgAN (e.g. rapidly progressive IgAN with crescents in >50% of glomeruli or minimal change GN with glomerular IgA deposits). - Secondary IgAN or diseases associated with glomerular deposits of IgA. - Additional other chronic renal disease. - Creatinine clearance below 30 ml/min (mean of 3 measurements).

发起方

RWTH Aachen